Hidradenitis Suppurativa
Conditions
Keywords
Apocrine glands, abcesses
Brief summary
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.
Interventions
DRUGadalimumab
Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
Sponsors
Abbott
Florida Academic Dermatology Centers
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Subjects with moderate to severe HS as defined by a HSSI \> 8 AND at least ONE of the following: 1. HS \>1 year duration with multiple ER or doctors visits related to HS 2. Intralesional kenalog injection \>5/year, however none within 2 weeks of entry 3. Failed systemic retinoids, but not within 3 months of entry 4. Failed at least one prior course of antibiotic therapy, which must not have been administered within 2 weeks of entry to the study (excluding the recommended antibiotic regimen given for evidence of active infection immediately before enrollment) 5. History of surgery (reconstructive), but not within 3 months of entry
Exclusion criteria
1. Women who are pregnant, nursing, or planning pregnancy within 6 months after the last injection (this includes father's who plan on fathering a child within 6 months after their last injection). 2. Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent). 3. If found to have an active infection, patients must have completed topical or oral antibiotic therapy at least 7 days before first injection. 4. Have a known history of serious infections (e.g., hepatitis, pneumonia or pyelonephritis) in the previous 3 months. 5. Have or have had an opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening. 6. Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g., nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly. 7. Have a concomitant diagnosis or history of congestive heart failure. 8. Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy and safety of adalimumab in subjects with moderate to severe hidradenitis suppurativa. Efficacy will be evaluated using the included Hidradenitis Suppurativa Severity Index (HSSI). | 13 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the role of TNF alpha in the pathogenesis of hidradenitis suppurativa. | 13 weeks |
| To evaluate the ability of adalimumab to maintain suppression of the disease. | 13 weeks |
Outcome results
None listed